APC resistance and third-generation oral contraceptives: Acquired resistance to activated protein C, oral contraceptives and the risk of thromboembolic disease

Human Reproduction

Volumn 16, Issue 1, 2001, Pages 3-8

  Gris, Jean Christophe ^a,b   Jamin, Christian ^c   Benifla, Jean Louis ^c   Quere, Isabelle ^a,b   Madelenat, Patrick ^c   Mares, Pierre ^a,b  

^a UNIV MONTPELLIER   (France)

^b NÎMES UNIVERSITY HOSPITAL   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Acquired resistance; Oral contraceptives; Protein C; Third generation; Thromboembolism

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ACTIVATED PROTEIN C RESISTANCE; BLOOD CLOTTING; BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFECT; HEMOSTASIS; HUMAN; MUTATION; NOTE; RISK FACTOR; THROMBOEMBOLISM;

EID: 0035187867     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/16.1.3     Document Type: Note

References (23)

1. Mutation in blood coagulation factor V associated with resistance to activated protein C
2. Hemostatic effects of oral contraceptives in women who developed deepvien thrombosis while using oral contraceptives
3. Acquired protein C resistance and oral contraceptives: Differences between two functional tests
4. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
5. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis
6. A new assay based on thrombin generation to detect both protein C and protein S deficiencies in plasma
7. Prospective evaluation of hemostatic system activation and thrombin potential in healthy women with and without factor V Leiden
8. Genetic susceptibility to pregnancy-related venous thromboembolism: Roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations
9. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism
10. Thrombin generation in plasma: Its assessment via the endogenous thrombin potential
11. Sensivity to activated protein C: Influence of oral contraceptives and sex
12. Renewed interest in haemostasis changes induced by oral contraceptives (OCs)
13. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation
14. Resistance to activated protein C in healthy women taking oral contraceptives
15. Resistance to activated protein C is reduced in women using oral contraceptives
16. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives
17. Low-dose oral contraceptives and acquired resistance to activated protein C: A randomised cross-over study
18. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study
19. APC resistance determined with the endogenous thrombin generation potential is associated with venous thrombosis: A blinded clinical evaluation
20. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways
21. Increased risk of venous thrombosis in oral-contraceptives users who are carriers of factor V Leiden mutation
22. Venous thrombomembolic disease and combined oral contraceptives: Results of international multicentre case-control study
23. Effect of different progestogens in low oestrogen oral contraceptives on venous thrombosis disease